Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.

@article{Chambers2005AntiBCT,
  title={Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.},
  author={Sharon A Chambers and D P Isenberg},
  journal={Lupus},
  year={2005},
  volume={14 3},
  pages={210-4}
}
The use of B cell depletion as a mode of treatment for non-Hodgkin's lymphoma was first utilized in 1997 when Rituximab, a chimeric human-mouse monoclonal antibody which has a high affinity to the CD20 antigen expressed on B cells, became available. Over 500000 lymphoma patients have been treated worldwide with this drug and it has a good safety record. The notion that B cells might be critical to the development of rheumatoid arthritis led to the extension of the use of B cell depletion to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS